Dear readers,
I read a lot of trial data. Most of it is incremental — a little more of this, a little less of that. Every so often a study lands on my desk that genuinely shifts how I think about a clinical problem, and I want to tell you about one that did this for me a couple of weeks ago.
It was published in Nature Medicine on May 13th. The trial is called ATTAIN-MAINTAIN, and it asks a question I get from patients more than almost any other.
The Question Behind the Study
If you’ve ever sat across from me and gotten serious about a GLP-1 — semaglutide, tirzepatide, any of them — you probably already know what comes next in the conversation. The weight loss is real. The metabolic benefits are real. But somewhere in the back of your mind there’s a quieter question: am I really going to do this forever?
It’s a fair thing to wonder. The shots aren’t always convenient. They’re expensive. They require refrigeration. Some people travel a lot, some people simply don’t love needles, and some people are ready to feel like they’re not perpetually in “treatment mode.”
The problem is that the data on what happens when people just stop these medications is not encouraging. The weight comes back. The blood pressure drifts back up. The cholesterol creeps. The insulin resistance returns. Obesity, like hypothyroidism or hypertension, doesn’t care that you’ve worked hard. It is a chronic condition, and it behaves like one.
So the real clinical question has never been should you stay on something forever or not? — it has been what do you stay on, and in what form, that you can actually live with for years?
That’s what made this study interesting to me.
What They Actually Did
The investigators took patients who had spent 72 weeks losing significant weight on injectable GLP-1s — either tirzepatide or semaglutide — and randomized them to do one of two things for the next year:
Switch to a once-daily oral pill called orforglipron (you may have seen it in the news under the brand name Foundayo, which was FDA-approved in April).
Or switch to a placebo.
That’s it. That’s the experiment. After a year on an injectable that had done its job, can a daily pill hold the line?
What They Found
The patients who switched to the oral kept most of their weight loss. The patients who switched to placebo did not.
Specifically: the tirzepatide group preserved about 75% of their weight loss on orforglipron, versus 49% on placebo. The semaglutide group preserved about 79% versus 38% on placebo. About two-thirds of the patients who’d previously achieved at least 15% body weight reduction were still holding that level a year later on the pill.
But the part that mattered most to me was what happened to the metabolic markers — the things I actually care about as a longevity physician. Hemoglobin A1c stayed at 5.2% (down from 5.6% pre-treatment). Waist circumference held. Blood pressure stayed lower. Triglycerides and non-HDL cholesterol stayed improved. The weight wasn’t the only thing that didn’t bounce back. The metabolic gains came along for the ride.
There’s also a charming little observation tucked into the discussion section: regardless of which injectable patients started on, both groups ended the year at almost the exact same body weight — 95.9 kg. The authors speculate this might hint at some kind of biological setpoint that orforglipron defends. Worth keeping an eye on as more data accumulates.
A Detail I Found Genuinely Useful
When this trial was designed, no one actually knew whether someone who’d been tolerating a high dose of tirzepatide could be dropped straight onto a meaningful dose of an oral GLP-1 without ending up miserable for a month with nausea. So they tested it. They moved patients directly from their injectable to 12 mg of orforglipron — skipping the slow stepwise titration that we normally use in patients new to the class.
Fewer than 5% had any meaningful GI symptoms in those first four weeks. Nobody had to dose-reduce. From a practical standpoint this is genuinely useful — it suggests we may not need to drag a transitioning patient through a long, uncomfortable ramp.
What I’m Taking Away From This
I want to be careful here, because I don’t think this study says what some headlines will say it says.
It does not say that the oral is as good as the injectable. The trial didn’t include a “keep taking your shot” comparison arm at all. It only compared the pill to nothing. So this isn’t really evidence about which therapy is most potent — it’s evidence about whether transitioning to a pill is a viable strategy compared to just stopping.
And it does that beautifully.
What this study tells me — and what I’ll be carrying into conversations with patients — is something like this: if you’ve done the work, if you’re metabolically stable, if you’re at a weight you’re happy with, and if the injectable is genuinely starting to feel unsustainable in your life, there is now a real, evidence-supported off-ramp. Not into nothing. Into something else.
For patients who are still actively losing, or who have diabetes, or who are doing beautifully on their current regimen — nothing about this study suggests changing course. The injectables remain our most powerful tools.
But the conversation has more room in it now than it did six months ago, and I think that matters.
One Last Thing
The other quiet undercurrent of this trial, and the reason I think it deserves attention beyond just the headline numbers, is the framing. The investigators were explicit that obesity is a chronic, relapsing disease, and that the cultural habit of stopping treatment once the scale cooperates is the same mistake we’d never make with blood pressure or thyroid hormone. We treat those forever, because the underlying biology is forever.
This is the way I’ve always practiced, and I’m glad to see the broader field catching up.
If you’re currently on a GLP-1 and wondering what the next chapter looks like, this is exactly the kind of thing I want us to talk through at your next visit. There are good options now, and there will be more.
To get started, call our office at 703-666-4144 or schedule a consultation with us.
Dr. Aleksandra Gajer
Founder, The Gajer Practice | Burke, Virginia
Board-Certified Physician | Functional & Performance Medicine
